Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation - PubMed (original) (raw)

Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation

D L Dankort et al. Mol Cell Biol. 1997 Sep.

Abstract

A number of cytoplasmic signaling molecules are thought to mediate mitogenic signaling from the activated Neu receptor tyrosine kinase through binding specific phosphotyrosine residues located within the intracellular portion of Neu/c-ErbB-2. An activated neu oncogene containing tyrosine-to-phenylalanine substitutions at each of the known autophosphorylation sites was generated and assessed for its specific transforming potential in Rat1 and NIH 3T3 fibroblasts. Mutation of these sites resulted in a dramatic impairment of the transforming potential of neu. To assess the role of these tyrosine phosphorylation sites in cellular transformation, the transforming potential of a series of mutants in which individual tyrosine residues were restored to this transformation-debilitated neu mutant was evaluated. Reversion of any one of four mutated sites to tyrosine residues restored wild-type transforming activity. While each of these transforming mutants displayed Ras-dependent signaling, the transforming activity of two of these mutants was correlated with their ability to bind either the GRB2 or SHC adapter molecules that couple receptor tyrosine kinases to the Ras signaling pathway. By contrast, restoration of a tyrosine residue located at position 1028 completely suppressed the basal transforming activity of this mutated neu molecule or other transforming neu molecules which possessed single tyrosine residues. These data argue that the transforming potential of activated neu is mediated both by positive and negative regulatory tyrosine phosphorylation sites.

PubMed Disclaimer

Similar articles

• Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer.
  Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, Muller WJ. Dankort D, et al. Mol Cell Biol. 2001 Mar;21(5):1540-51. doi: 10.1128/MCB.21.5.1540-1551.2001. Mol Cell Biol. 2001. PMID: 11238891 Free PMC article.
• Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.
  Dankort D, Jeyabalan N, Jones N, Dumont DJ, Muller WJ. Dankort D, et al. J Biol Chem. 2001 Oct 19;276(42):38921-8. doi: 10.1074/jbc.M106239200. Epub 2001 Aug 10. J Biol Chem. 2001. PMID: 11500516
• Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation.
  Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ. Luttrell LM, et al. J Biol Chem. 1997 Feb 14;272(7):4637-44. doi: 10.1074/jbc.272.7.4637. J Biol Chem. 1997. PMID: 9020193
• A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides.
  van der Geer P, Wiley S, Lai VK, Olivier JP, Gish GD, Stephens R, Kaplan D, Shoelson S, Pawson T. van der Geer P, et al. Curr Biol. 1995 Apr 1;5(4):404-12. doi: 10.1016/s0960-9822(95)00081-9. Curr Biol. 1995. PMID: 7542991

Cited by

• Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
  Najjar MK, Manore SG, Regua AT, Lo HW. Najjar MK, et al. Genes (Basel). 2022 Nov 8;13(11):2065. doi: 10.3390/genes13112065. Genes (Basel). 2022. PMID: 36360302 Free PMC article. Review.
• Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs.
  Pinet L, Assrir N, van Heijenoort C. Pinet L, et al. Biomolecules. 2021 Nov 14;11(11):1690. doi: 10.3390/biom11111690. Biomolecules. 2021. PMID: 34827688 Free PMC article. Review.
• AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.
  Al-Zahrani KN, Abou-Hamad J, Pascoal J, Labrèche C, Garland B, Sabourin LA. Al-Zahrani KN, et al. Breast Cancer Res. 2021 May 13;23(1):55. doi: 10.1186/s13058-021-01435-6. Breast Cancer Res. 2021. PMID: 33985544 Free PMC article.
• Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random.
  Pinet L, Wang YH, Deville C, Lescop E, Guerlesquin F, Badache A, Bontems F, Morellet N, Durand D, Assrir N, van Heijenoort C. Pinet L, et al. Biophys J. 2021 May 18;120(10):1869-1882. doi: 10.1016/j.bpj.2021.03.005. Epub 2021 Mar 17. Biophys J. 2021. PMID: 33741354 Free PMC article.
• HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
  Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. Ruiz-Saenz A, et al. Cancer Res. 2018 Jul 1;78(13):3645-3658. doi: 10.1158/0008-5472.CAN-18-0430. Epub 2018 May 14. Cancer Res. 2018. PMID: 29760043 Free PMC article.

References

1. 1. EMBO J. 1994 Mar 15;13(6):1331-40 - PubMed
2. 1. Mol Cell Biol. 1994 Apr;14(4):2777-85 - PubMed
3. 1. Cancer. 1994 Jul 1;74(1 Suppl):381-400 - PubMed
4. 1. Mol Cell Biol. 1994 Aug;14(8):5192-201 - PubMed
5. 1. Mol Cell Biol. 1994 Aug;14(8):5441-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Gene Ontology

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal